Ajanta Pharma Ltd (AJANTPHARM) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management confirmed new competition for a key US product, expecting a sales normalization and margin moderation in H2 after a very strong H1.
- The full-year EBITDA margin guidance of 27% implies a drop to ~26% in H2, down from 29% in H1, due to business mix changes and higher spending.
- FY27 R&D spending will be stepped up to ~5% of revenue, while capex is guided at 400 crores, signaling continued investment in pipeline and capacity.
Performance Overview
- The company reported a strong Q2 FY27, with revenue growing 33% and PAT increasing by 49% year-over-year.
- Performance was robust across all business verticals, including a significant turnaround in the Asia branded generics business.
- The US generics and Africa institution businesses delivered exceptionally strong, albeit unsustainable, growth in the first half.
- The India business continued to outperform the Indian Pharmaceutical Market (IPM), improving its overall market ranking to 23rd.
- The balance sheet strengthened, with return on capital employed improving to 41% and return on net worth to 31% as of September 2026.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.